Vall d’Hebron studies the potential of a new exoskeleton model in the early stages of spinal cord injury rehabilitation

This marks the first time a wearable exoskeleton has been used during the acute phase of traumatic spinal cord injury, enabling more personalised and intensive therapy for patients.

17/11/2026

Vall d’Hebron University Hospital, together with the National Hospital for Paraplegics in Toledo and the University of Lleida, is participating in a multicentre clinical trial to evaluate the use of a new exoskeleton in the rehabilitation of patients with acute and subacute traumatic spinal cord injuries. Unlike previous research into exoskeletons, which has focused primarily on people with chronic spinal cord injuries, this study explores for the first time the potential of this technology during the early stages of injury, up to six months after the accident, when patients are still undergoing recovery.

Loss of mobility has a major impact on the quality of life of neurological patients, particularly those who have suffered an acute traumatic spinal cord injury. For these patients, rehabilitation is not simply a necessity, but a bridge towards greater independence and reintegration into the community. However, rehabilitation tools used in public healthcare hospitals have evolved very slowly over recent decades. Standard treatment relies on devices such as parallel bars, body-weight-supported gait training systems, standing frames and splints. In recent years, efforts have been made to introduce robotic-assisted gait training devices, as several studies have shown that they can improve treatment effectiveness. Nevertheless, current devices have several limitations that hinder their implementation: they cost more than €150,000, weigh over 30 kilograms and take more than 20 minutes to adjust from one patient to another.

The device selected for the study is the ABLE exoskeleton, designed by the Catalan company ABLE Human Motion, which aims to overcome these limitations. It is lighter than conventional devices, allows for quicker fitting and incorporates software that adapts to each patient's functional abilities, adjusting the level of assistance to provide personalised therapy.

“The aim of the study is to assess the clinical and biomechanical benefits of using the exoskeleton during the acute and subacute phases of acute traumatic spinal cord injury, as well as the effectiveness of exoskeleton-assisted treatment during this stage of rehabilitation,” explains Dr Lluïsa Montesinos, Head of the Spinal Cord Injury Unit within the Physical Medicine and Rehabilitation Department at Vall d’Hebron University Hospital and Head of the Physical Medicine and Rehabilitation Research Group at the Vall d’Hebron Research Institute (VHIR).

The study is currently recruiting patients and has already enrolled five patients at Vall d’Hebron University Hospital and ten at the National Hospital for Paraplegics in Toledo. The University of Lleida will be responsible for assessing the economic impact of using robotic gait therapy during this acute phase of traumatic spinal cord injury.

The study will analyse the clinical benefits and cost-effectiveness of using robotic rehabilitation within Spain's National Health System, considering its impact on patients and their families, as well as on the healthcare system as a whole.

The aim of this exoskeleton is to provide patients with acute traumatic spinal cord injuries with the best possible rehabilitation, helping to improve their quality of life in the medium and long term.

Vall d’Hebron University Hospital currently has three exoskeletons, which are used in different areas of rehabilitation as part of its commitment to incorporating new technologies and innovative tools into patient care.

Share it:

Related news

Related professionals

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.